Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC)

• Published in: European journal of cancer (1990) 1998-11, Vol.34 (12), p.1974-1976
• Main Authors: Boni, C., Savoldi, L., Bisagni, G., Ceci, G., Crinò, L., De Lisi, V., Di Costanzo, F., Lasagni, L., Manenti, A.L., Moretti, G., Rondini, E., Sassi, M., Zadro, A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; cisplatin; Cisplatin - administration & dosage; continuous infusion; Female; Humans; Infusions, Intravenous; Lung Neoplasms - drug therapy; Male; Medical sciences; Middle Aged; Mitomycins - administration & dosage; MVP; non-small cell lung cancer; Pharmacology. Drug treatments; Prospective Studies; randomised phase III study; Vindesine - administration & dosage
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/S0959-8049(98)00231-7

The aim of this randomised trial was to compare the efficacy of bolus versus continuous infusion cisplatin combined with mitomycin C and vindesine (MVP) for chemotherapy-naive patients with stage IIIB–IV non-small cell lung cancer (NSCLC). 97 patients (49 given bolus cisplatin—arm A and 48 given continuous infusion cisplatin—arm B) were evaluable for response. In arm A, 2 patients achieved a complete response (CR), 21 achieved a partial response (PR), whilst in arm B, 14 patients achieved a PR (29%) ( P=0.07). Median survival was 8 months in both arms. Myelosuppression was the most frequent and severe toxicity, with a higher incidence of grade 3–4 leucopenia in arm A when compared with arm B (44% versus 25%). In conclusion, there is no advantage for a cisplatin 5 day infusion in the MVP regimen.